Share Name Share Symbol Market Type Share ISIN Share Description
Woodford Patient Capital Trust Plc LSE:WPCT London Ordinary Share GB00BVG1CF25 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.20p -2.18% 53.80p 7,828,741 16:35:11
Bid Price Offer Price High Price Low Price Open Price
54.10p 54.50p 56.00p 51.80p 54.70p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments -3.85 -0.47 488.8

Woodford Patient Capital (WPCT) Latest News (3)

More Woodford Patient Capital News
Woodford Patient Capital Takeover Rumours

Woodford Patient Capital (WPCT) Share Charts

1 Year Woodford Patient Capital Chart

1 Year Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

Intraday Woodford Patient Capital Chart

Intraday Woodford Patient Capital Chart

Woodford Patient Capital (WPCT) Discussions and Chat

Woodford Patient Capital Forums and Chat

Date Time Title Posts
19/6/201901:24::: WOODFORD PATIENT CAPITAL TRUST :::8,220
06/6/201913:15Woodford Patient Capital Trust201

Add a New Thread

Woodford Patient Capital (WPCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-06-18 17:45:0253.683,6301,948.40O
2019-06-18 16:44:4354.53448244.29O
2019-06-18 16:27:2953.8015,1798,166.00O
2019-06-18 16:08:3153.804,0002,152.00O
2019-06-18 15:35:1153.80386,961208,185.02UT
View all Woodford Patient Capital trades in real-time

Woodford Patient Capital (WPCT) Top Chat Posts

Woodford Patient Capital Daily Update: Woodford Patient Capital Trust Plc is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker WPCT. The last closing price for Woodford Patient Capital was 55p.
Woodford Patient Capital Trust Plc has a 4 week average price of 51.80p and a 12 week average price of 51.80p.
The 1 year high share price is 91p while the 1 year low share price is currently 51.80p.
There are currently 908,639,238 shares in issue and the average daily traded volume is 9,186,819 shares. The market capitalisation of Woodford Patient Capital Trust Plc is £488,847,910.04.
jonwig: @ Spec - WPCT have permission to issue new shares (granted at AGM), and last time they were issued at NAV, benefitting WPCT at the expense of WEIF. If they repeat the exercise, it would probably have to be on the same terms, which would surely cause an outcry over at WEIF as the discount has more than doubled to 30+%. That means WEIF would be paying 45% more than the existing share price! I'm sure Link would block it if they could. But then, further down the line, these WPCT shares are weakly held ... what price WPCT when they're dumped? What a mess!
orinocor: The WPCT share price is holding up very well. I'd have thought shorters would have been all over this like a rash. Wrong again.
spectoacc: @Jonwig - seems to me the unlisted stuff doesn't count if it's declared it'll float in next 12 months, and the cancellation/reissue was to extend/give another 12 month period. Could be wrong, but looks highly suspect, nearly as bad as the Guernsey listings :) Since I'm anti-Woodford but not necessarily anti-WPCT, how about this - the forced selling from WEIF collapse (not far off the right word) actually benefits WPCT as it gets to buy what may yet turn out to be some decent punts, at full NAV and not at WPCT share price. So whilst we look to buy into decent co's forced down by Woodford's selling (VSL, NRR etc), WPCT gets to do that with the unlisted stuff. Woodford's stock-picking record may imply otherwise of course. [Edit: "After Oxford Nanopore told Mr Woodford of its flotation plans, the fund manager was able to sell his 2.15m shares back to the company, which were then cancelled and reissued as new securities, said two people close to the situation.“In effect this buys Woodford 12 months,” one analyst said."]
ltcm1: johnwag I don't understand why you think Tom Winnerfrith could drive the WPCT price down when WPCT has an enterprise value of nearly a billion pounds, plus is merely a vehicle for investing in other companies. The discount to NAV can only be a result of market sentiment unless the stock was highly illiquid, which WPCT is not. It will soon narrow if people perceive WPCT to be a good bargain. Today the NAV has fallen again but the stock is rising so we are seeing that happen right now.
topvest: Yes, he sold some NSF - see the RNS. I’m inclined to agree that this is a sensible deal for both entities, albeit it should have been using a lower WPCT share price as a reference point. Whether the 5 holdings transferred are worth anything like the transfer value is highly questionable though. Time will tell.
robow: from Investment Trust Insider Seneca buys back into fallen Woodford Patient Capital Seneca Investment Managers has swung back behind Woodford Patient Capital Trust (WPCT) arguing its depressed share price does not reflect the progress former star fund manager Neil Woodford has made with the portfolio of largely unquoted, early-stage healthcare companies. The Liverpool-based multi-asset manager revealed it placed small positions in Patient Capital in its Seneca Global Income & Growth (SIGT) investment trust and Seneca Diversified Growth and Seneca Diversified Income open-ended funds. Seneca said it bought the £707 million trust when its shares traded 16% below net asset value (NAV), suggesting the trade took place in December as markets retrenched over fears of rising US interest rates and a trade war with China. The discount has has since narrowed to 11% giving Seneca an early gain as the shares have rallied from a post-Christmas low of 79.2p to 85p today. Sentiment towards the trust remains poor, however, with the shares well below the 100p price at which they launched nearly four years ago and their current NAV per share of nearly 97p. Seneca chief investment officer Peter Elston said the firm invested as ‘we feel the discount to net asset value does not reflect the recent advances demonstrated by underlying early-stage companies within the portfolio’. This is a change of heart for Seneca, which sold its stake in the trust three years ago claiming that it had been overvalued, making a near 20% profit for its Diversified Growth fund. Richard Parfect, a fund manager at Seneca, told the Mail on Sunday that the decision to reinvest followed good news from some of the trust’s holdings. This includes Proton Partners International, which is benefiting from wider use of proton beam therapy for cancer patients, as well as DNA sequencing business Oxford Nanopore Technologies and biopharmaceutical group Autolus. Parfect met Woodford (pictured) in November and said the huge wave of criticism the manager had endured for the poor three-year performance of his flagship Woodford Equity Income fund as well as Patient Capital was an ‘inevitable result of having been put on a pedestal’. ‘Such swings in emotion create a dislocation between price and value,’ he told the newspaper. Woodford, the former star manager of Invesco Perpetual's Income and High Income funds and the Edinburgh (EDIN) investment trust, has had a tough time since branching out on his own five years ago. Last November the trust faced further pressure as Swiss hedge fund manager Lombard Odier started shorting the shares. However, later that month WPCT announced three ‘significant milestones’ with news of major collaborations by Immunocore, Mission Therapeutics, and Spin Memory – all held by the trust. Shortly afterwards it received a further boost when Stifel analyst Iain Scouller upgraded the trust to ‘buy’ saying investors had become too gloomy and appeared to have given up on a recovery. Like Seneca, Scouller had recommended selling WPCT in the months after its launch when enthusiastic investors pushed the shares to a high of 115p before reality and a series of setbacks sent the stock sliding. Seneca Global Income & Growth is a £79 million trust investing defensively in a mix of mainstream and specialist assets in the UK and overseas. Over five years its share price plus dividends have delivered a total return of 54.9%, ahead of the FTSE All-Share's 33.6% return and its own benchmark of beating inflation by 6% a year but slightly below the 59.1% average of trusts in the AIC Flexible sector. Its holding in Patient Capital will sit with a number of other investment trusts and companies SIGT uses to gain exposure to specialist markets, such as International Public Partnership (INPP), a listed infrastructure fund, Doric Nimrod Air Two (DNA2) and the recently launched Merian Chrysalis (MERI), which buys stakes in companies expected to float on the stock market.
daffyjones: UtilityWise had already fallen 98% from 2014 until yesterday. All the while Woodford the bagholder kept adding more shares, claiming he was "buying in to attractive share price weakness" and that the company was "fundamentally undervalued" (this when the share price was 214p). Now the share price craters a further 64% this morning to 2p after the company basically announces it is going to struggle to remain a going concern. UTW is a former WPCT holding; Woody still owns 27% of the company across his WEIF and WIFF portfolios, with a further 2.7% held as part of the Omnis Income and Growth fund which he manages. Woodford held on to his shares even as all the directors sold up, with the founder dumping his entire holding last November. Woody is the archetypal bagholder.
oiltakeyouhomeagaincaitlin: Does jonwig hold any WPCT shares? Erm NO. Does jonwig own any Woodford shares? Erm NO. Does jonwig intend to hold any of these shares? Erm NO. Woodford is, he claims, "untrustworthy". Does jonwig know anything substantive about the valuation of the unquoted shares in WPCT? Erm NO. Does jonwig have the ability to show that redemptions in the Woodford Funds will have a profound effect, or any effect, on WPCT? Erm NO. Does jonwig have any real knowledge that is not clearly in the public domain about WPCT? Erm NO. Does jonwig have the knowledge, ability, rationale, to conduct a campaign over hundreds of boring obsessive posts attempting to destroy WPCT? Erm NO. Has jonwig had any success in his long repetitive campaign in bringing down the Share Price of WPCT? Erm NO (Hell, NO!) Does ANYBODY admire jonwig for his futile attempts to destroy Woodford and WPCT? There may be two or three others of the same ilk (or is it Ilkley?)lurking about this thread, but they don't count because they are essentially stupid, too. So, Erm, NO What then is Jonwig? An admirable public-spirited activist? Erm NO. He is, put quite simply, an UNSUCCESSFUL TROLL! LOL
daffyjones: CAPITA - A BAGHOLDER'S TALE June 2014 - CPI share price 1137 – CPI makes the top ten in the launch portfolio of Woodford's flagship fund. Feb 2016 – share price 1030 - "Capita weakened sharply after issuing its full year results. The company continues to show strong organic growth, and both earnings and dividend growth remain at attractive levels. Investors appear to have focused on the company’s net debt, however, which came in slightly higher than expected and some analysts now fear that a rights issue may be required to delever the balance sheet. We think that this is unlikely and are much less concerned about the strength of Capita’s balance sheet. We believe it remains well-placed to deliver very attractive rates of growth.” Sep 2016 – 670 – “The largest detractor from performance was Capita, which issued a profit warning towards the end of the month. We have always accepted that there was some cyclicality within Capita’s business but a number of other issues have arisen, some of which are one-off in nature. As you would expect, we have met the management and are reassured that the company is already doing some of the things it needs to do in order to restore the business to a healthier growth trajectory. Although the market is clearly worried about the sustainability of Capita’s dividend and the prospect of a dilutive rights issue, we are confident that the dividend is safe and that an equity issue will not be required. The market’s reaction looks disproportionate. We added slightly to the holding towards the end of the month at a very depressed share price level." Dec 2016 - 535 – “We believe the market has over-reacted to the series of profit warnings. In our view, the share price now profoundly undervalues the fundamental long-term attractions of this business. At times like this, it is essential that one does not compound the impact of a fundamental disappointment through an emotional reaction to a share price fall." Jan 2017 – 509 – “it is critical that we do not compound that mistake through an emotional reaction to the disappointment of the share price fall. Our view is that the market has over-reacted to this series of negative trading updates. In turn, this has driven Capita’s share price way below the intrinsic value of the business. We have, therefore, retained conviction in the long-term investment case and took advantage of the depressed share price to add to the fund’s position in the company.” Feb 2017 – 416 – “We have said before that we were disappointed by events at Capita last year, which combined to undermine market confidence in the business and the credibility of management forecasts. We have spoken to management several times as these issues have unfolded, including a recent conversation with the new chairman who appears keen to ensure that the business takes appropriate steps to move on from last year’s challenges. In our view, Capita’s share price continues to profoundly undervalue the fundamental long-term attractions of the business. It will take time to rebuild credibility and value at the company but we believe the management changes announced earlier this month will mark an important step on that journey.” Dec 2017 – 392 – “Capita performed poorly, following the release of its interim results. Although the results were broadly in line with expectations, there were a number of complicating one-off elements and a mixed outlook statement. The shares declined by 12% on the day of the results which looks very harsh to us in the context of Capita’s already low valuation. The shares yield over 7% here which suggests that some investors fear a dividend cut may be required. Clearly that eventuality cannot be completely ruled out, but having met Jon Lewis during the month, we are reassured that decisions around capital structure and the dividend will be informed by a clearer long-term strategy for the business. In the meantime, we have maintained the portfolio’s exposure to this business, seeing the potential for significant value creation in the future as Capita is restored to the high quality, successful and well-run business that it used to be.” Jan 2018 – 182 – “Since the profit warning on Wednesday, Capita’s share price has broadly halved, which has clearly been unhelpful to recent performance. I am pleased that we have seen from the company what we thought would be coming. This is a complete reset for Capita. The new chief executive, Jonathan Lewis, has mapped out a clear new direction of travel for the business and it is one with which I completely agree. This reset has been met with a massive fall in the share price from an already very depressed level. In the current market conditions, perhaps we should not have expected anything else. After all, Capita represents many of the things that this market loathes at the moment – it is exposed to the UK economy. This is the reality of what we have been writing about for some time now. Markets are being driven by momentum. Valuation is irrelevant – it simply does not matter in the stock market at the moment. This has been a poor investment, but it is one that has the capacity to become a significantly better one from here. I would go as far as to say that the business will be in better shape at the end of 2018 than it was in 2016. It will have infinitely better leadership, a stronger balance sheet, better cash flow, more conservative accounting policies and a lower pension deficit. The mistake I have made, albeit I didn’t know it at the time, was in owning Capita in 2016. It is not a mistake to own it now. And so, I will not be compounding the previous error by behaving in an irrational and valuation insensitive way now. I would be doing you, my investors, a massive injustice if I was to abandon the investment discipline that has guided me for 30 years in this industry.” Nov 2018 – 107 – Woody finally sells out completely, with the shares down 90% from the launch of his fund.
saltraider: Hands up ... I am really not a 'harsh' sort of a person. Apologies to @orinocor for being excessively terse. The trouble is that there are a fair few people around and about who are trying to manipulate the WPCT share price ... and using some pretty dubious means to do it. They are shorting WPCT and trying to use other 'communications' avenues to add to the pressure on the price at the same time. That includes pushing blatantly fake news. When you step in (@orinocor) and make negative statements based on apparently zero knowledge of the basic WPCT concept, you are just accidentally (and ignorantly ... sorry!) aiding and abetting the manipulators.
Woodford Patient Capital share price data is direct from the London Stock Exchange
Your Recent History
Woodford P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190619 02:47:21